Ophthalmology

Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.

Carlos Quezada Ruiz, MD, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”

Retina Technologies Inc. is working on a modular digital vision screening platform it says will provide vision testing for the early detection of eye disorders.

Professor Anat Loewenstein, MD, discusses data regarding the efficacy of faricimab at targeting both the VEGF and Ang2 pathways in patients with neovascular AMD and diabetic macular edema.

In a patient survey, 66% of respondents said AI plays a large role in their diagnosis and treatment and thought it was important.

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

EyePoint Pharmaceuticals hopes to usher in a new paradigm of retinal eye disease treatments with their candidate EYP-1901.

The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).

As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Karl Csaky, MD and Fredrick Ferris III, MD, identified in 2007—Dr. Csaky reinforces on the importance of preserving the central retinal tissue.

The American Academy of Ophthalmology applauded Congress for reaching the 290-consponsor milestone for the proposal. By reaching the two-thirds majority of bipartisan support in Congress, the bill is eligible for inclusion on the Consensus Calendar under new rules that were established in 2019.

Apellis revealed 18-month data for their investigational C3 therapy pegcetacoplan, unveiling continuous lesion growth reduction in eyes with geographic atrophy with monthly and every-other-month injections.

Results from our recent poll regarding Retina World Congress 2022 attendance indicate that while many retina specialists will attend the Congress, the majority will not be in Fort Lauderdale, Florida.

The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.

Dr. Diana Do presents data on a novel patient-reported outcome instrument for patients with proliferative diabetic retinopathy with the hope of capturing the burden of the disease and treatment.

According to the company, the trial did not demonstrate efficacy on the key clinical endpoints. As a result, Oxurion will now shift its focus to the Phase 2 development program for THR-149, which recently demonstrated a compelling safety and efficacy profile for the treatment of DME.

Treatments include tinted spectacles and/or contact lenses, low-vision aids, atropine drops, and patching for amblyopia, as well as eye muscle surgery for the nystagmus or any anomalous head posture and associated strabismus.

According to an e-poster presented by Jagadesh C. Reddy, MD, and Harini Indusekar, BScOptom, at the ASCRS in Washington, D.C., patients who have pre-existing DR are less likely to achieve Snellen 20/40 or better vison after cataract surgery compared with the patients with diabetes but without DR.

The Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Colorado, revealed a variety of advancements in technology, pivotal trials and clinical trial design.

Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.

Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.

Eva Chamorro, PhD, MSc, points out that myopia control spectacle lenses affect the diurnal rhythms in the AL in young adult human and produced a small short-term increase in the AL that varies in intensity and time interval for each of the 3 studied lenses.

THR-687 is currently being evaluated in a phase 2 clinical trial in patients with DME. The first data from the dose-optimization study is expected to be released in the first half of 2022.

Mike Watson, Vice President of OraNet, unpacks some of the most pressing challenges to clinical research in today’s climate.

During a presentation at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Yuichi Hori, MD, PhD, and colleagues found that taping the top border of a surgical mask to a clinicians’ skin reduces the potential for ocular surface damage resulting from expirations of air reaching the ocular surface during the COVID-19 pandemic.

The study found no association between treatment and the risk of chronic kidney disease or end-stage renal disease.

In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting, Osama Ibrahim Hirayama, MD, and colleagues offered results that demonstrating that anisometropia and astigmatic error were greater among the patients with high myopia compared with the other groups. Compared with the subjects with no myopia, those with high myopia reported significantly more dryness, less photophobia, and less pain.

Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.

The axitinib intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.

Investigators from the New York University Grossman School of Medicine presented data at the ARVO 2022 annual meeting that concluded mapping of the relative cerebrovascular reactivity in the murine brain showed widespread brain changes resulting from the chronic IOP elevation and demonstrates vascular involvement in glaucoma both within and beyond the primary visual pathways.

At ARVO 2022, Jason S. Slakter, MD, presents data on the efficacy and safety of OPT-302 when combined with ranibizumab for polypoidal choroidal vasculopathy.